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We also determined the higher sP-selectin level in plasma 
of SP MS subjects than in the control group. Based on the 
obtained results, we might conclude that during the course 
of SP MS platelets are chronically activated and display 
hyperreactivity to physiological agonists, such as ADP or 
collagen.
Keywords Multiple sclerosis · Blood platelets · Flow 
cytometry · Prothrombotic risk
Introduction
Multiple sclerosis (MS) is a chronic, demyelinating 
immune-mediated disease of the central nervous system 
(CNS) with axonal degeneration and astrogliosis [1]. There 
are three main clinical types of MS, defined as relapsing-
remitting (RR), secondary progressive (SP), and primary 
progressive (PP) with a progressive-relapsing (PR) sub-
type [2]. It is generally very difficult to predict the clini-
cal course of MS [3]. Histopathologically, MS is consid-
ered as a heterogenous neurological disease with a variable 
clinical course and several pathophysiological mechanisms, 
such as focal inflammatory infiltrates, demyelination, glio-
sis, axonal/neuronal damage within the CNS, and in some 
cases remyelination and repair mechanisms [4, 5]. A great 
number of patients with the most common type RR MS 
gradually develop neurological deterioration independent 
of relapses. When axons lose their ability to regenerate, 
RR MS patients develop SP MS dominated by neuroaxonal 
degeneration. The axonal loss is responsible for the tran-
sition from RR MS to progressive types of the disease. In 
SP MS, the permanent clinical disability correlates with 
axonal injury as well brain and spinal cord atrophy [6–10] 
in SP MS and in RR MS active tissue injury is associated 
Abstract The epidemiological studies confirm an 
increased risk of cardiovascular disease in multiple scle-
rosis, especially prothrombotic events directly associated 
with abnormal platelet activity. The aim of our study was 
to investigate the level of blood platelet activation in the 
circulation of patients with chronic phase of multiple scle-
rosis (SP MS) and their reactivity in response to typical 
platelets’ physiological agonists. We examined 85 SP MS 
patients diagnosed according to the revised McDonald’s 
criteria and 50 healthy volunteers as a control group. The 
platelet activation and reactivity were assessed using flow 
cytometry analysis of the following: P-selectin expression 
(CD62P), activation of GP IIb/IIIa complex (PAC-1 bind-
ing), and formation of platelet microparticles (PMPs) and 
platelet aggregates (PA) in agonist-stimulated (ADP, colla-
gen) and unstimulated whole blood samples. Furthermore, 
we measured the level of soluble P-selectin (sP-selectin) in 
plasma using ELISA method, to evaluate the in vivo level 
of platelet activation, both in healthy and SP MS subjects. 
We found a statistically significant increase in P-selectin 
expression, GP IIb/IIIa activation, and formation of PMPs 
and PA, as well as in unstimulated and agonist-stimulated 
(ADP, collagen) platelets in whole blood samples from 
patients with SP MS in comparison to the control group. 
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with inflammation but in SP MS the inflammatory response 
occurs at least partly behind the blood–brain barrier (BBB), 
which makes it more difficult to treat [11]. In MS, the 
immune cells, mainly autoreactive T cells (CD4+, CD8+), 
infiltrate the CNS and release proinflammatory cytokines 
that activate phagocytic cells (macrophages), leading to 
the inflammation of white matter and subsequent myelin 
destruction [5, 12].
The blood platelets possess a large variety of com-
pounds stored in α-granules, numerous membrane recep-
tors, immunomodulatory mediators, and cell adhesion mol-
ecules, through which they affect the permeability of BBB. 
Blood platelets are responsible for the infiltration of autore-
active T cells which form new neuroinflammatory lesions 
in CNS [13–15]. Due to neuroinflammation disorders of 
the BBB, platelets rapidly adhere to the endothelium cells, 
became activated, and contribute to neurovascular inflam-
mation caused by multiple interactions with endothelial and 
inflammatory cells [16, 17]. Therefore, in the inflamed neu-
ronal tissue platelets contribute to neurovascular inflamma-
tion and neuronal disease in several ways [18, 19]. Platelets 
may modulate inflammation by their receptor-dependent 
interaction with leukocytes and the release of bioactive 
mediators, mainly matrix metalloproteinases and different 
chemokines, and it is one of the most important mecha-
nisms since MS is mediated via migration of leukocytes 
and monocytes from the peripheral circulation to CNS 
[20]. Under inflammatory conditions, stimulated platelets 
rapidly adhere to the endothelium or to the subendothelial 
extracellular matrix at sites of vascular endothelial injury 
[14, 21–23]. The platelets are also a major source of IL-1α 
which can activate brain endothelium and enable the entry 
of white blood cells leading to cerebrovascular inflamma-
tion [24].
It has been proved that blood platelets might be a key 
player in the development of inflammation in early stage of 
MS [23]. RR MS and SP MS are two different types of MS 
characterized by different ongoing pathogenic processes. 
RR MS is characterized mainly by inflammation processes, 
while SP MS (the chronic progressive stage) is character-
ized with the domination of neurodegenerative processes. 
The clinical symptoms are also different. Currently, many 
studies targeted one type of MS to make their study more 
specific [25, 26]. The most important is to know the dif-
ferences between these two basic types in this heterogenic, 
complex disease.
The platelet activation and the role of platelets in hemo-
static mechanisms in a further development of the disease 
in the secondary progressive stage are the subject of our 
intensive studies for some years. Our previous findings sug-
gest that platelet activation may be an epiphenomenon con-
sequent to the disease processes in MS, probably secondary 
to endothelial injury, which causes the exposure of platelets 
to a variety of stimuli. We have demonstrated in vitro that 
isolated platelets obtained from patients with SP MS have 
adhered significantly stronger to typical subendothelial 
thrombogenic proteins—collagen and fibrinogen—than 
platelets from healthy controls [27]. Furthermore, we have 
shown an increased platelet aggregation in SP MS meas-
ured in platelet-rich plasma (PRP) due to ADP, collagen, or 
arachidonate action [27, 28].
In the current study, we used flow cytometry, a sensitive 
method routinely used both in the diagnosis of health dis-
orders, as well as in basic research. The platelet subpopula-
tions (normal platelets, microparticles (PMPs), and platelet 
aggregates (PA) in whole blood were distinguished from 
other cells based on the presence of constitutive platelets’ 
membrane receptor (CD61) on their surface and light-scat-
tering properties of platelets, which are linked to cell size 
and granularity. Additionally, the use of different antigen-
specific and fluorophore-conjugated primary antibodies 
allowed the quantitative determination of target antigen 
expression on the cells. In our experiments, we measured 
the level of expression of platelet activation marker CD62P 
(P-selectin) and the activation of integrin receptor GP IIb/
IIIa. Using flow cytometry technique, it was possible to 
analyze the biological activity of platelets in their natural 
environment, immediately after blood collection. There-
fore, the obtained results, for the first time, allowed us to 
directly understand the degree of activation and reactivity 
of platelets in the circulation of patients with SP MS. All 
studies were performed without and with exposure to the 
physiological agonists: ADP and collagen.
In addition, we studied the level of the soluble adhesion 
molecule sP-selectin (soluble P-selectin) in plasma from 




Flow cytometry reagents such as anti-CD61/PerCP, anti-
CD61/PE, anti-CD61/FITC, anti-CD62/PE, PAC-1/FITC, 
and Cellfix were obtained from Becton Dickinson (San 
Diego, CA, USA). ADP and collagen were purchased in 
Chrono-Log (Havertown, PA, USA). All other chemicals 
were of analytical grade or highest quality available prod-
ucts. Human sP-selectin ELISA kit (Invitrogen).
Patients and samples
The human blood samples were collected into CPDA-1 
(citrate phosphate dextrose adenine-1) bags from 85 
patients suffering from secondary progressive (SP) course 
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of MS. Patients were observed for one year before and 
diagnosed according to the revised McDonald’s criteria. 
SP MS was ascertained as defined by Lubin et al. [29]. The 
SP MS can be recognized when initial relapsing-remitting 
course is followed by progression, with or without occa-
sional relapses, minor remissions, and plateaux. Clinical 
characteristics of SP MS patients are as follows: mean age 
48.6 ± 12.5 years, BMI 21.1 ± 9.7, disability status scale 
(EDSS) 4.5 ± 1.8, and mean disease duration 12.3 ± 9.5 
years. Blood samples were delivered from Neurologi-
cal Rehabilitation Division III General Hospital in Lodz, 
Poland. Platelet counts of SP MS patients were measured 
in the clinical laboratories of the hospital. Normal ranges 
of values were used for reference. Mean platelet counts for 
both patients (n = 85) and control (n = 50) were within the 
normal range (150–400 × 103/μL). Patients did not receive 
any medications modifying platelet function.
Human blood samples obtained from healthy volunteers 
were a control (n = 50). Healthy volunteers were not taking 
any medications, and they have never been diagnosed with 
MS or other chronic disease, any neurological or hormonal 
illness, and any chronic inflammatory disease. Both groups 
(patients and control) were matched by age and sex.
Fifty two female patients with SP MS and 31 healthy 
female subjects were considered for the study. None of 
these women were undergoing hormone replacement 
therapy.
All blood samples (from patients and control group) 
were collected in the morning (between 8 am and 10 am) 
in fasting status and stored using the same protocol. The 
protocol and all procedures were done according to the 
Helsinki Declaration and were approved by the Ethics 
Committee of the Medical University of Lodz, Poland, 
RNN/260/08/KB, and the Ethics Committee of the Faculty 
of Biology and Environmental Protection of University of 
Lodz, Poland, No. 5/KBBN-UŁ/II/2013.
Flow cytometry analysis
The changes in the activation and reactivity of resting or 
agonist-stimulated blood platelets were assessed by three-
color flow cytometry. The fresh whole blood samples, 
without agonist or activated with ADP (20  µM, 10  min., 
37 °C) or collagen (20  µg/ml, 10  min., 37 °C), were fixed 
in 1% Cellfix solution (9:1) for 1h at 37 °C and stained with 
anti-CD61/PerCP, anti-CD62P/PE, and PAC-1/FITC anti-
bodies (30 min in dark, RT). Before analysis, the prepared 
samples were dissolved in 0.9% NaCl (20:1) and vortexed. 
Fluorescence of 10,000 platelets (CD61/PerCP-positive 
objects) was measured with an LSR II Flow Cytometer 
(Becton Dickinson, San Diego, CA, USA). The platelets 
were distinguished from other cells based on forward light 
scatter (FSC) vs. side light scatter (SSC) plot characteristics 
on a log/log scale (first gate) and by positive staining with 
monoclonal antibody CD61/PerCP (second gate). The 
percentages of CD62P-positive platelets and PAC-1-pos-
itive platelets were calculated relative to the total number 
of platelets (CD61-positive cells) present in each sample. 
Antibody-positive platelets were defined as exhibiting flu-
orescence intensities greater than 99% of unstained sam-
ples. To compensate for non-specific immunofluorescence, 
the percentages of CD62P- and PAC-1-positive platelets 
were obtained after subtracting the percentage of positive 
platelets when the antibodies were replaced by the isotype-
matched PE- and FITC-conjugated immunoglobulin con-
trols for CD62P (isotype IgG1) and PAC-1 (isotype IgM), 
respectively.
Additionally, the fractions of platelet-derived micropar-
ticles (PMPs) and platelet aggregates (PA) in unstimulated 
or agonist-activated whole blood samples were measured in 
the experiments of P-selectin expression and PAC-1 bind-
ing to platelets. Platelet microparticles and platelet–platelet 
or platelet–leukocyte aggregates were distinguished from 
platelets (CD61-positive objects) based on their size and 
granularity on the forward light scatter (FSC) vs. side light 
scatter (SSC) plots. All data analyses were performed in 
FACSDiva version 6.1.2.
sP‑selectin measurement
In plasma obtained from patients with SP MS and healthy 
volunteers, the concentration of sP-selectin was determined 
by immunosorbent method (ELISA). The level of sP-selec-
tin in human plasma was measured using P-selectin (solu-
ble) Human ELISA Kit (Invitrogen) according to the manu-
facturer’s protocol. The level of sP-selectin in plasma was 
determined from a standard curve expressed as ng/mL.
Statistical analysis
Data were statistically elaborated. The expression lev-
els of platelet activation and aggregation biomarkers are 
presented as mean value ± SD. The Shapiro–Wilk test 
was used to verify whether the data were normally dis-
tributed. The significance of differences between samples 
and controls was determined with unpaired Student’s t or 
Mann–Whitney U test. The data were analyzed using Stats-
Direct statistical software V. 2.7.2. The value of p < 0.05 
was considered as statistically significant.
Results
To measure the activation of platelets and their reactiv-
ity to physiological agonists (ADP and collagen) in whole 
blood obtained from SP MS patients or healthy controls, 
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we performed three-color flow cytometry as an investiga-
tion method. Based on flow cytometry analysis, our results 
clearly indicated the statistically significant increase in 
both basal and agonist-treated platelet activation states in 
patients with SP MS compared with healthy individuals.
Using forward light scatter (FSC) vs. side light scatter 
(SSC) plot characteristics, we determined in CD61/PerCP-
positive objects the formation of platelet aggregates as well 
as the release of platelet-derived microparticles. Using ref-
erence beads, we estimated gates: CD61/PerCP-positive 
objects with FSC lower than  102.3 were characterized as 
PMPs, while objects with FSC higher than  104 were char-
acterized as PA. In samples of non-stimulated platelets, we 
observed the augmented basal level of PA (2.3-fold vs. con-
trol; p < 0.05) (Fig. 3a). Moreover, we showed the increased 
pool of PMPs (2.5-fold vs. control; p < 0.01) observed in 
FSC vs. SSC cytometry dot plots (Fig. 4a). We chose the 
representative dot plots of percentage of PA and PMPs: for 
non-stimulated control, 1.8% PA and 1.6% PMPs (Fig. 7a) 
and for non-stimulated SP MS, 4.9% PA and 3.6% PMPs 
(Fig. 7d). The values of the PA and PMPs was respectively 
2.7 times and 2.5 times higher in SP MS than in control.
Additionally, in CD61/PerCP-positive objects PE and 
FITC fluorescence was detected. Gates were estimated 
based on unstained probes. In case of PE, the objects with 
fluorescence level higher than  102.7 were characterized as 
platelets with surface expression of P-selectin, while in the 
case of FITC the objects with level of fluorescence higher 
than  103.05 were characterized as platelets with PAC-1 
antibody binding. The percentages of CD62P-positive 
platelets and PAC-1-positive platelets were calculated rela-
tive to the total number of platelets (CD61-positive cells) 
present in each sample. The level of basal platelet activa-
tion was measured by the surface expression of two main 
platelet markers: CD62P and PAC-1 binding to activated 
form of GPIIb/IIIa. The resting platelets in whole blood 
samples obtained from SP MS patients showed 2.3-fold 
higher CD62P expression (p < 0.05) (Fig.  1a) and 1.5-
fold higher level of PAC-1 binding to activated form of 
GPIIb/IIIa(p < 0.05) (Fig.  2a) in comparison to the con-
trol group. Figure  5 shows the representative histograms 
of the percentage of CD62P-positive platelets in samples 
from non-stimulated healthy control, which is 1.9% (A), 
and non-stimulated blood of SP MS patients, which is 
5.9% (D). The histograms of the percentage of PAC-1-pos-
itive platelets for the same analyzed subjects are shown in 
Fig.  6. The ratio between healthy non-stimulated control 
(1.7%) (Fig. 6a) and non-stimulated SP MS platelets (4.3%) 
(Fig. 6d) is 2.5.
In our study, we also compared the level of blood platelet 
responsiveness to two physiological agonists. The activa-
tion of platelets in whole blood treated with ADP (20 µM) 
was statistically significantly higher in SP MS patients 
compared to the control group, which we observed in the 
expression of CD62P (over 60%; p < 0.001) (Fig.  1b) and 
PAC-1 binding (over 30%; p < 0.02) (Fig.  2b). However, 
Fig. 1  Expression of P-selectin on resting (a) or agonist-stimulated 
platelets: ADP 20 µM (b) and collagen 20 µg/ml (c) in whole blood 
samples obtained from SP MS patients and healthy controls. Analyses 
were performed in whole blood of healthy volunteers (control) and 
patients with SP MS. The blood platelets were distinguished based on 
the expression of CD61/PerCP. For each sample, 10 000 CD61-posi-
tive objects (platelets) were acquired. For the assessment of P-selectin 
expression, samples were labeled with fluorescently conjugated mon-
oclonal antibody CD62P/PE. Results are shown as the percentage of 
platelets expressing CD62P. Statistical analysis was performed using 
Mann–Whitney U test
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Fig. 2  Expression of the active form of GPIIb/IIIa on resting (a) 
or agonist-stimulated platelets: ADP 20 µM (b) and collagen 20 µg/
ml (c) in whole blood samples obtained from SP MS patients and 
healthy controls. Analyses were performed in whole blood of healthy 
volunteers (control) and patients with SP MS. The blood platelets 
were distinguished based on the expression of CD61. For each sam-
ple, 10,000 CD61-positive objects (platelets) were acquired. For the 
assessment of P-selectin expression, samples were labeled with fluo-
rescently conjugated monoclonal antibody PAC-1-FITC. Results are 
shown as the percentage of platelets binding PAC-1/FITC. Statistical 
analysis was performed using Mann–Whitney U test
Fig. 3  Formation of platelet aggregates in control (a) and agonist-
stimulated platelets: ADP 20  µM (b) and collagen 20  µg/ml (c) in 
whole blood samples obtained from SP MS patients and healthy 
controls. The fraction of platelet aggregates was distinguished from 
platelets (CD61-positive objects) based on their size and granularity 
on the forward light scatter (FSC) vs. side light scatter (SSC) plots. 
CD61-positive objects with FSC higher than  104 were characterized 
as platelet aggregates. In each sample, 10,000 CD61-positive objects 
(platelets) were measured. Statistical analysis was performed using 
Mann–Whitney U test
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according to the representative histograms (Figs. 5, 6), the 
difference between a randomly selected healthy control 
and SP MS subject may be much greater. The percentage 
of CD62P-positive platelets for healthy controls was 21.2% 
(Fig.  5b), and for SP MS sample it was 37.5% (Fig.  5e), 
expressing an increase more than 80%. The percentage of 
PAC-1-positive control platelets was 7.7% (Fig.  6b) and 
that of SP MS platelets 12.8% (Fig.  6e), so an increase 
was over 60%. In ADP-stimulated platelets, we observed 
the augmented level of PA (1.9-fold vs. control; p < 0.002) 
(Fig.  3b). This was confirmed by the representative dot 
plots of PA for healthy subjects (3.5%) (Fig.  7b) and SP 
MS patients (7.2%) (Fig.  7e). Similarly, we showed an 
increased pool of PMPs (2.3-fold vs. control; p < 0.002). 
The random combination of two representative dot plots 
of the percentage of PMPs for healthy control, i.e., 5.8% 
(Fig. 7b), and SP MS sample, i.e., 10.2% (Fig. 7e), gave a 
1.8-fold increase of PMPs in SP MS.
The incubation of whole blood with 20 µg/ml of colla-
gen also resulted in the statistically significant increase of 
blood platelet reactivity in SP MS patients compared to 
the control group. We noticed in SP MS group a twofold 
increase in CD62P expression (p < 0.001) (Fig.  1c), over 
a 1.9-fold increase in PAC-1 binding (p < 0.001) (Fig. 2c) 
and an increase in the formation of PA and PMPs: 2.1-
fold (p < 0.05) (Fig. 3c) and 2.3-fold (p < 0.001) (Fig. 4c), 
respectively, vs. healthy subjects. The representative histo-
grams of the expression level of P-selectin (Fig. 5) and the 
active form of GPIIb/IIIa (Fig.  6) on collagen-stimulated 
platelets from healthy subject (C) and SP MS patient (F) 
confirmed a twofold increase in the expression of CD62P 
and a 1.8-fold increase in PAC-1 binding. However, the 
representative dot plots of PMPs and PA for typical healthy 
control (C) and for selected patient (E) indicated a 1.4-fold 
increase in PMPs and a 1.7-fold increase in PA (Fig. 7).
Additionally, we compared the level of sP-selectin 
released into plasma. From the results obtained in ELISA 
test, we observed that the concentration of sP-selectin 
was statistically significantly higher (174 ± 8  ng/mL vs. 
123 ± 6 ng/mL; p < 0.0001) in patients with SP MS than in 
healthy controls (Fig. 8).
Discussion
Besides participation in hemostasis, blood platelets may be 
involved in the propagation and development of major dis-
eases like neurodegenerative diseases, including MS [30]. 
Habets et al. examined the potential role of platelets in joint 
inflammation in rheumatoid arthritis (RA) and showed the 
increased expression of P-selectin, the elevated produc-
tion of sCD40L, and the increase in platelet aggregation in 
patients with RA compared to healthy subjects. Moreover, 
these studies demonstrated the elevated plasma levels of 
TNF-α and PAF in RA, that is, the factors responsible for 
platelet activation through the arachidonic acid pathway. 
The authors demonstrated the positive correlation between 
Fig. 4  Formation of platelet-derived microparticles in control (a) 
and agonist-stimulated platelets: ADP 20 µM (b) and collagen 20 µg/
ml (c) in whole blood samples obtained from SP MS patients and 
healthy controls. The fraction of platelet-derived microparticles was 
distinguished from platelets (CD61-positive objects) based on their 
size and granularity on the forward light scatter (FSC) vs. side light 
scatter (SSC) plots. CD61-positive objects with FSC lower than  102.3 
were characterized as PMPs. In each sample, 10 000 CD61-positive 
objects (platelets) were measured. Statistical analysis was performed 
using Mann–Whitney U test
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activation of platelets and disease activity thus suggesting 
a role form platelets function in the course of autoimmune 
disease accompanied by inflammation [31].
Our previous studies clearly indicate that platelets iso-
lated from patients with SP MS are more activated and are 
easily stimulated by exogenous stimuli, analogous to physi-
ological agonist [27]. Our observations strongly support the 
results from earlier literature [32].
In the present work, for the first time, we assessed the 
degree of platelet activation in their natural environment, 
which is the whole blood analyzed immediately after blood 
collection. Blood platelets are readily activated and dam-
aged during the procedure of isolation and purification. The 
possibility to apply flow cytometry to assess the platelets in 
whole blood without isolation of platelets or platelet-rich 
plasma significantly reduces the risk of creating artifacts. 
The measurement in whole blood using flow cytometric 
assay determines the activation state of circulating plate-
lets, if it is done without the addition of external platelet 
agonists. Among the existing reports confirming the plate-
let abnormalities in MS patients, there are no studies of 
biological activity of platelets in whole blood using flow 
cytometry. The study of Sheremata et al. using flow cytom-
etry method in PRP proved that blood platelets are signifi-
cantly activated in RR MS patients [21]. In general, there 
are only very few data describing the physiology of plate-
lets in the secondary progressive phase of MS. Roshanisef 
at et al. based on Poisson regression estimated the relative 
risk of cardiovascular disease in patients with MS: for RR 
MS reaching 2.16 and for SP MS reaching 3.4 [33]. They 
also showed that the risk of thromboembolic events asso-
ciated with the procoagulant platelet activation increases 
with disease progression.
Among the microparticles from various types of cells, 
the most numerous are PMPs which represent up to 90% 
of all of them. They are the result of shedding of cell mem-
branes and the formation of vesicles, so they are accepted 
markers of wear and disintegration of cells. An increased 
level of PMPs is typical of some diseases [34]. It is well 
known the important role of PMPs released from acti-
vated platelets, to catalyze the coagulation cascade. This 
is accomplished by an activation-dependent membrane 
Fig. 5  Representative histograms of the expression level of P-selec-
tin on non-stimulated platelets (shown as control) (a, d) and on stimu-
lated platelets with ADP (b, e) or collagen (c, f) in whole blood sam-
ples obtained from SP MS patients (d–f) and healthy controls (a–c). 
The blood platelets in whole blood were distinguished based on the 
expression of CD61 conjugated with PerCP. For each sample, 10 000 
CD61-positive objects (platelets) were acquired. The blood platelets 
were labeled with monoclonal antibody anti-CD62P (PE)
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inversion or “flip-flop” by which normally inward-facing 
phospholipids become exposed to plasma. These anionic 
phospholipids form procoagulant surface by promoting 
coagulation factors into their active complexes, leading to 
the generation of thrombin that converts fibrinogen to the 
fibrin plug [23]. Some epidemiological studies confirm 
that MS increases the risk of cardiovascular events, mainly 
venous thromboembolism, ischemic strokes, and myocar-
dial infarction [35]. Moreover, PMPs reveal most of the 
platelet membrane proteins, including the matrix metallo-
proteinases which have been generally recognized as major 
participants in the disruption of BBB in MS, by enabling 
the migration of white blood cells to the CNS [16]. As has 
been shown, PMPs may play an important role in neuro-
degenerative diseases and their increased expression is an 
accepted marker of platelet activation [36, 37]. Our findings 
in patients with SP MS are in line with the results obtained 
by Sheremata et al., which indicated the elevated levels of 
PMPs in RR MS patients [21]. However, thanks to the anal-
ysis conducted in whole blood, we could, for the first time, 
successfully confirm the speculation presented in the ear-
lier literature that platelets are chronically activated in MS. 
Flow cytometry method allows for comparative analysis in 
study and control samples, not only a fraction of PMPs, but 
also the pool of aggregates, as objects larger than a single 
cell. We demonstrated the increased percentage of plate-
let–platelet and/or platelet–leukocyte aggregates presented 
in whole blood of patients with SP MS, relative to healthy 
controls (Fig. 3a).
For the analysis of platelet surface marker expression on 
the surface of platelets in non-stimulated whole blood, the 
number of associated monoclonal antibodies, expressed as 
the fraction of antigen-positive platelets relating to some 
glycoproteins platelet membrane (e.g., P-selectin, GPIIb/
IIIa) is a marker for platelet activation in circulation [38]. 
The presence and quantification of the active complex of 
glycoproteins IIb and IIIa (acting as the main receptor for 
fibrinogen) on the platelet surface depend on the state of 
platelet activation. GP IIb/IIIa belongs to the constitu-
ent antigens, which are always present on the cell surface, 
Fig. 6  Representative histograms of the expression level of active 
form of GPIIb/IIIa on non-stimulated platelets (shown as control) (a, 
d) and on stimulated platelets with ADP (b, e) or collagen (c, f) in 
whole blood samples obtained from SP MS patients (d–f) and healthy 
controls (a–c). The blood platelets in whole blood were distinguished 
based on the expression of CD61 conjugated with PerCP. For each 
sample, 10 000 CD61-positive objects (platelets) were acquired. The 
blood platelets were labeled with monoclonal antibody PAC-1 (conju-
gated with FITC) against the active form of GPIIb/IIIa
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including non-stimulated platelets, but their number has 
been growing significantly as a result of platelet activa-
tion, due to the release of contents from intracellular gran-
ules [39]. The conformational changes in GPIIb/IIIa com-
plex upon platelet activation lead to binding of fibrinogen 
and von Willebrand factor (vWF), and, in consequence, to 
platelet aggregation [40, 41].
Previous reports have shown the presence of platelets 
in the inflamed spinal cord tissue in the course of murine 
experimental autoimmune encephalomyelitis (EAE) [18], 
as well as in human MS lesions [42]. Moreover, microar-
ray analysis of differentially expressed genes in MS plaques 
obtained at autopsy proved an upregulation of the genes for 
platelet-specific GPIIb in patients with chronic demyelinat-
ing disease [42]. Similar results were obtained in a murine 
model of EAE. As compared to non-inflamed spinal 
cords, the elevated level of GPIIb mRNA was found in the 
inflamed spinal cords of mice on day 21 after EAE induc-
tion using myelin oligodendrocyte glycoprotein. Moreover, 
the authors suggested that the contribution of platelets to 
EAE is probably associated with the activation of GPIIb/
IIIa complex, because blockade of this receptor reduced 
EAE severity in mice [18]. Our results are in line with the 
Fig. 7  Representative dot plots of the percentage of platelet-derived 
microparticles and platelet aggregates in a population of resting 
platelets (shown as a control) (a, d) and in a population of stimu-
lated platelets with ADP (b, e) or collagen (c, f) in whole blood sam-
ples obtained from SP MS patients (d–f) and healthy controls (a–c). 
The blood platelets in whole blood were distinguished based on the 
expression of CD61 conjugated with PerCP. For each sample, 10,000 
CD61-positive objects (platelets) were acquired
Fig. 8  Level of sP-selectin in plasma obtained from SP MS patients 
and healthy controls. sP-selectin was determined by ELISA method. 
Statistical analysis was performed using unpaired Student’s t test 
(p < 0.0001)
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mentioned reports. We have shown an increased surface 
expression of GPIIb/IIIa active complex on platelets in 
whole blood of patients with SP MS. A significant increase 
was about 55% compared to healthy controls (Fig. 2a).
One of the main biomarkers of platelet activation is 
P-selectin, a glycoprotein presented in α-granules of resting 
platelets. The activated platelets dynamically change their 
shape and release the contents of α-granules, secreting a 
variety of cytokines, chemokines, and growth factors. Dur-
ing platelet activation, CD62P appears on their surface and 
allows platelet–platelet or platelet–leukocyte interaction via 
P-selectin glycoprotein ligand-1 (PSGL-1) presented on 
leukocytes’ surface (mainly on monocytes and neutrophils). 
The formation of platelet–leukocyte aggregates leads to 
the production of inflammatory molecules, such as leu-
kotrienes and cytokines, and augments the inflammation. 
Platelet–leukocyte interaction may occur as a consequence 
of platelet activation and possibly plays a key role in the 
deposition of activated platelets in demyelinating lesions in 
MS, which leads to brain neurodegeneration [21, 43].
The expression of CD62P on the platelet surface reflects 
cell degranulation, and therefore the measurement of its 
level is a useful tool to monitor the activation status of 
platelets in vitro and in vivo [44, 45]. Based on flow cyto-
metric measurements, we have shown a significantly higher 
(about 115%) basal P-selectin expression on the plate-
let surface in SP MS patients in comparison to the con-
trol group (Fig.  1). Our findings are similar to the results 
obtained by Sheremata et  al., who demonstrated signifi-
cantly elevated expression of CD62P in RR MS [21]. Sher-
emata et  al. using flow cytometric method demonstrated 
that blood platelets were significantly activated in patients 
with RR MS. The authors, for the first time, observed that 
the levels of accepted markers of platelet activation, PMPs 
and CD62, were, respectively, over twofold and 1.7-fold 
higher in patients with RR MS in comparison to healthy 
controls [21]. We noticed the slightly higher platelet acti-
vation in patients with SP MS: the pool of PMPs (2.5-fold 
vs. control) and the expression of CD62 (2.3-fold vs. con-
trol) were elevated. Both in our study and that of Sheremata 
et al., the level of circulating platelet microaggregates was 
extended.
CD62 belongs to antigens that are temporarily expressed 
on the platelet surface upon activation and over time 
undergo proteolytic cleavage into plasma. Platelets are the 
major source of circulating soluble P-selectin. Detection 
of elevated level of this antigen in plasma proves that the 
previous episodes of platelet activation took place in cir-
culation [28]. The elevated plasma level of sP-selectin is a 
biomarker of vascular disease and is also associated with 
several inflammatory disorders. Soluble P-selectin has 
functional effects by activating leukocytes and promot-
ing their adhesion and subsequent recruitment to arterial 
and venous micro- and macrocirculation [43, 46]. The 
increased expression of sP-selectin level was observed in 
the murine model of MS [47]. Kuenz et  al. also investi-
gated platelet activation by the measurement of sP-selectin 
plasma concentration in MS patients. The authors observed 
a higher level of sP-selectin in RR MS compared to the 
group of healthy blood donors [43]. In our research, we 
noticed not only the raised level of P-selectin membrane 
expression, but also the increased plasma level of sP-selec-
tin (over 41%) in SP MS patients in comparison to healthy 
subjects (Fig. 8). Our results argue in favor of the high fre-
quency of episodes of platelet activation in the circulation 
of patients with SP MS. This is evidenced by the increased 
level of P-selectin detected both on the platelet surface and 
in plasma.
With the additional application of exogenous activat-
ing factors (identical to physiological) into the samples of 
whole blood, cytometry method allows to determine the 
reactivity of platelets ex  vivo in their physiological envi-
ronment. Platelet response to the physiological agonists 
is a measure of the availability and depletion of circulat-
ing platelets. To determine the functionality of platelets 
in SP MS, we measured the levels of activation markers 
after stimulation with ADP or collagen. In this study, we 
showed the enhanced reactivity of platelets in whole blood 
of patients with SP MS. By measuring the expression levels 
of P-selectin (Figs. 1b, c, 4) and GPIIb/IIIa (Figs. 2b, c, 5) 
and determining the fraction of circulating PA (Figs. 3b, c, 
6) and PMPs (Figs. 4b, c, 6), we showed that platelets of 
patients with SP MS were fully functional, but exhibited an 
increased response to the agonists, characteristic of chronic 
activation.
Conclusions
In the present work, for the first time, we demonstrated the 
significantly higher platelet activation in SP MS patients 
in their natural environment, which is the whole blood 
analyzed immediately after collection. Therefore, we can 
conclude that the disease progression of SP MS is associ-
ated with platelet hyperactivity. Furthermore, augmented 
levels of platelet aggregation and generation of PMPs can 
be the main causes of the increased risk of thromboem-
bolic events, which are observed in patients with SP MS. 
Moreover, as we have shown platelets from patients with 
SP MS are more sensitive to agonists and are more easily 
activated. We can therefore assume that platelets, which are 
involved in the development of inflammatory and autoim-
mune responses, as well as disorders of hemostasis, are one 
of the key targets of therapy in SP MS. The understanding 
of molecular processes of platelet function underlying the 
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SP MS might be beneficial and may improve more specific 
treatments of SP MS in the future.
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